🔴 Sellas Life Sciences is trading 13.1% down as investors await blinded REGAL results

Sellas Life Sciences is trading 13.1% down at $10.58 as investors await preliminary topline results from its blinded Phase 3 REGAL trial.

• On October 28, the company announced the trial reached its 80th event, triggering final analysis; preliminary topline results are expected this quarter.
• The blinded milestone does not reveal whether the treatment met its primary endpoint.
• Coverage also cited disclosure-timing concerns and legal-investigation headlines, but available reporting does not establish that today’s announcement directly caused the decline.